Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma by Jurczak, Wojciech et al.
ORIGINAL ARTICLE
Phase IIa study of the CD19 antibody MOR208 in
patients with relapsed or refractory B-cell non-
Hodgkin’s lymphoma
W. Jurczak1*, P. L. Zinzani2, G. Gaidano3, A. Goy4, M. Provencio5, Z. Nagy6, T. Robak7, K. Maddocks8,
C. Buske9, S. Ambarkhane10, M. Winderlich10, M. Dirnberger-Hertweck10, R. Korolkiewicz10 &
K. A. Blum8
1Department of Hematology, Jagiellonian University, Krako´w, Poland; 2Institute of Hematology “L. e A. Sera`gnoli”, University of Bologna, Bologna; 3Division of
Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy; 4John Theurer Cancer Center, Hackensack University Medical
Center, Hackensack, USA; 5Department of Medical Oncology, University Hospital Puerta De Hierro, Madrid, Spain; 6First Department of Internal Medicine,
Semmelweis University, Budapest, Hungary; 7Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland; 8Division of
Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA; 9Comprehensive Cancer Center Ulm,
Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm; 10MorphoSys AG, Planegg, Germany
*Correspondence to: Dr Wojciech Jurczak, Department of Hematology, Jagiellonian University, Kopernika 17, 30-501 Krako´w, Poland. Tel: þ48-60233829;
E-mail: wojciech.jurczak@uj.edu.pl
Background: This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered,
humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin’s lymphoma (NHL). CD19 is broadly
expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells.
Patients and methods: Patients aged18 years, with R-R NHL progressing after1 prior rituximab-containing regimen were
enrolled into subtype-specific cohorts: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), other indolent (i)NHL
and mantle cell lymphoma (MCL). Treatment was MOR208, 12mg/kg intravenously, weekly, for 8weeks. Patients with at least
stable disease could continue treatment for an additional 4weeks. Those with a partial or complete response after 12weeks
could receive extended MOR208 treatment (12mg/kg, either monthly or every second week) until progression. The primary end
point was overall response rate.
Results: Ninety-two patients were enrolled: DLBCL (n¼ 35), FL (n¼ 34), other iNHL (n¼ 11) and MCL (n¼ 12). Responses were
observed in DLBCL, FL and other iNHL cohorts (26%, 29% and 27%, respectively). They lasted12months in 5/9 responding
patients with DLBCL, 4/9 with FL and 2/3 with other iNHL. Responses in nine patients are ongoing (>26months in five
instances). Patients with rituximab refractory disease showed a similar response rate and progression-free survival time to
patients with non-refractory disease. The most common adverse events (any grade) were infusion-related reactions (12%) and
neutropenia (12%). One patient experienced a grade 4 infusion-related reaction and eight patients (9%) experienced grade 3/4
neutropenia. No treatment-related deaths were reported.
Conclusions: MOR208 monotherapy demonstrated promising clinical activity in patients with R-R DLBCL and R-R FL, including
in patients with rituximab refractory tumors. These efficacy data and the favorable safety profile support further investigation of
MOR208 in phase II/III combination therapy trials in R-R DLBCL.
ClinicalTrials.gov number: NCT01685008.
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Introduction
The B-lymphocyte antigen CD19 is expressed throughout B-cell
development until terminal plasma cell differentiation [1].
Expression is not seen in stem cells or most other normal cell
types. CD19 enhances B-cell antigen receptor signaling by ampli-
fication of phosphoinositide-3-kinase and Bruton’s tyrosine kin-
ase activity [1, 2], which plays a crucial role in tumor cell
proliferation and survival [3]. CD19 is broadly and homoge-
neously expressed across different B-cell malignancies including
diffuse large B-cell lymphoma (DLBCL), follicular lymphoma
(FL) and chronic lymphocytic leukemia (CLL) [4, 5]. It has
also been shown that expression is preserved during lymphoma
treatment [6, 7]. Taken together, these characteristics suggest
that CD19 represents an attractive target antigen in patients with
B-cell non-Hodgkin’s lymphoma (NHL).
MOR208 (XmAb
VR
5574, MOR00208) is an Fc-engineered,
humanized, CD19 monoclonal antibody. The Fc enhancement,
comprising the introduction of S239D and I332E amino acid
substitutions, leads to a potentiation of antigen-dependent
cell-mediated cytotoxicity (ADCC) and antigen-dependent cell-
mediated phagocytosis compared with the unmodified parental
immunoglobulin G1 CD19 antibody, as demonstrated through
in vitro and in vivo analyses in leukemia and lymphoma model
systems. MOR208 also directly induces cytotoxicity, potentially
by disrupting B-cell antigen receptor signaling [8, 9]. A phase I
dose-escalation study in 27 patients with relapsed or refractory
(R-R) CLL showed MOR208 to be safe and well tolerated and
provided initial evidence of clinical activity; the highest tested
intravenous dose of 12mg/kg was recommended for phase II
studies [10].
This phase IIa study was designed to investigate the antitumor
activity of single-agent MOR208 in adult patients with R-R B-cell
NHL who had received at least one prior rituximab-containing
regimen.
Patients and methods
Study design and participants
This is an open-label, single-arm, multicenter phase IIa trial with a two-
stage design. Patients aged18 years with histologically confirmed
DLBCL, FL, other indolent (i)NHL or mantle cell lymphoma (MCL),
which had progressed after at least one prior cycle of a rituximab-
containing regimen (defined as rituximab plus chemotherapy or at least
four weekly administrations of single-agent rituximab), were eligible (for
full criteria, see supplementary Methods, available at Annals of Oncology
online). Data on tumor expression levels of CD19 and CD20, and cell of
origin for cases of DLBCL, were not available at the time of enrollment.
Patients were considered to have rituximab refractory disease if they
had no response, or a response lasting<6months, to a prior rituximab-
containing therapy.
The study protocol was approved by the institutional review boards of
each participating center and the study was conducted in accordance
with the Declaration of Helsinki. All patients provided written informed
consent before the initiation of any study-related procedure.
Treatment comprised MOR208 12mg/kg, administered as an intra-
venous infusion over 2 h on days 1, 8, 15 and 22 of a 28-day cycle, for two
cycles (supplementary Figure S1, available at Annals of Oncology online).
After 8 weeks of dosing, patients with a partial or complete response or
stable disease could continue for one additional cycle (i.e. 12 weeks of
dosing overall). Patients with a documented partial or complete response
at the end of cycle 3 could continue to receive MOR208 as extended treat-
ment at a dose of 12mg/kg, with the frequency of administration decided
by the investigator, as either monthly or every second week, until disease
progression or the occurrence of unacceptable toxicity. This flexibility in
extended treatment scheduling allowed for investigator optimization ac-
cording to lymphoma subtype and other clinical considerations.
For the first three MOR208 infusions in cycle 1, there was a mandatory
prophylactic premedication [optional thereafter if no infusion-related re-
action (IRR) occurred] including antipyretics, histamine H1 receptor
blockers and glucocorticosteroids (methylprednisolone 80–120mg intra-
venously or equivalent).
Study assessments
The primary end point was the overall response rate (sum of partial and
complete responses), as assessed by the investigators according to the
International Working Group criteria [11] (for the detail of investigator
and central assessments, see supplementary Methods, available at
Annals of Oncology online). Adverse events (AEs), assessed continuously
throughout the treatment, were coded according to the Medical
Dictionary for Regulatory Activities, version 15.1, and graded according
to National Cancer Institute Common Terminology Criteria for Adverse
Events, version 4.0.
Serial blood samples were collected for pharmacokinetic, immunogen-
icity and biomarker analyses. Peripheral B-, T- and natural killer (NK)
cell counts were assessed locally by flow cytometry. Additionally, if pa-
tients consented to FCGR2A/FCGR3A genotype analyses, a mucosal
cheek swab was taken for DNA extraction. Genotyping was carried out by
dideoxysequencing of polymerase chain reaction-amplified products
(Eurofins Genomics, Ebersberg, Germany).
Statistical considerations
The primary end point, overall response rate, was assessed in the modi-
fied intent-to-treat (mITT) population, comprising all patients who
received at least one dose of study drug (same definition for the safety
population). Patients without any post-baseline response assessment
were to be included as non-responders. Secondary end points included
duration of response, progression-free survival (PFS), proportion of pa-
tients with stable disease, safety, pharmacokinetics and the immunogen-
icity ofMOR208.
A two-stage design was used to minimize exposure of patients with
NHL subtypes not responding to MOR208. In stage 1,10 patients were
to be enrolled into each of four NHL subtype-specific cohorts; DLBCL,
FL, other iNHL and MCL. If2 patients (20%) in a cohort had a partial
or complete response after 8–12weeks of treatment, then20 additional
patients with that NHL subtype were to be enrolled. The planned sample
size was consequently between 40 and 120 patients. No formal statistical
hypothesis testing was planned. For the post hoc PFS subgroup analysis
of high versus low peripheral NK cell counts at baseline, the variable cut-
off was determined by receiver operating characteristic curve analysis.
Results
Patients
Between 23 April 2013 and 4 November 2014, 92 patients were
enrolled, including 35 with DLBCL, 34 with FL, 11 with other
iNHLs (nine with marginal zone lymphoma; two with CLL),
and 12 with MCL. The patient disposition is summarized in sup-
plementary Figure S2, available at Annals of Oncology online.
Baseline characteristics showed a heavily pretreated population,
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with more than half of patients having rituximab refractory dis-
ease (Table 1).
Efficacy
Based on responses in stage I, both the DLBCL and FL cohorts
were expanded in stage 2 to 35 and 34 patients, respectively.
Responses (two complete, one partial) were also seen for three
patients with marginal zone lymphoma of 11 patients enrolled in
the other iNHL cohort. However, due to the underlying hetero-
geneity of other iNHL subtypes, this cohort was not expanded.
No responses were reported for 12 patients in the MCL cohort,
and enrollment was stopped as per study design; stable disease
was reported for six (50%) of these patients.
After the completion of stage 2, responses were seen in 9 (26%)
of 35 patients (two complete, seven partial) in the DLBCL cohort
and 10 (29%) of 34 patients (three complete, seven partial) in the
FL cohort (Table 2), with a median time to response of 2.0 and
2.8months for DLBCL and FL, respectively (Figure 1). Stable dis-
ease was reported for a further 5 (14%) and 16 (47%) patients, re-
spectively. Sixteen out of 92 patients (17%) discontinued
treatment before the first post-baseline radiological tumor assess-
ment with unconfirmed disease progression and were counted as
non-responders, including 10 of 35 (29%) with DLBCL. Among
patients with rituximab refractory disease, the response rate was
21% (5/24 patients) in DLBCL, 24% (4/17) in FL and 20% (1/5)
in other iNHL.
Tumor shrinkage data were available for central radiology as-
sessment for 23 patients with DLBCL, 29 with FL and 7 with other
iNHLs. The percentage change in indicator lesion size from base-
line for individual patients during the course of the study is
shown in supplementary Figure S3, available at Annals of
Oncology online and the best change illustrated in supplementary
Figure S4, available at Annals of Oncology online. These measure-
ments demonstrated that initial partial responses could deepen
over the course of the treatment. A degree of target lesion shrink-
age was also apparent in 19 of 23 patients with stable disease
(5 with DLBCL, 11 with FL and 3 with other iNHLs).
Responses were seen across all patient subgroups defined by
FCGR2A codon 131 genotypes and FCGR3A codon 158 geno-
types (supplementary Table S1, available at Annals of Oncology
online).
Duration of response and PFS
The median duration of response was 20.1months (range 1.1–
26.5) for DLBCL and not yet reached (range 2.6–26.6months)
for FL. Responses lasting12months were observed in five pa-
tients with DLBCL, four with FL and two with other iNHL
(Figure 1). At the cut-off date, three patients with DLBCL, four
with FL and two with iNHL were still in remission and on study
treatment. Of the 10 responders with rituximab refractory disease
(eight with partial and two with complete responses), six had a re-
sponse duration of10months (26.0, 20.1 and 13.2months in
the DLBCL cohort; 10.6, 12.0 and 26.6 in the FL cohort).
With a median follow-up time of 21months, the median PFS
was 2.7months (95% CI 2.1–15.4) in patients with DLBCL,
8.8months (95% CI 5.3–27.1) in patients with FL and not
reached (95% CI 2.0–NA) in patients with other iNHL
(supplementary Figure S5A–C, available at Annals of Oncology
online). The 12-month PFS rate was 39% in the DLBCL and FL
subgroups. Notably, PFS was similar in patients with rituximab
non-refractory versus rituximab refractory tumors [median 6.6
versus 5.3months, respectively, hazard ratio (HR) 0.87, 95% CI
0.47–1.60, P¼ 0.67; supplementary Figure S5D, available at
Annals of Oncology online]. Exploratory post hoc analysis re-
vealed that patients with a baseline peripheral NK cell
count above a threshold of 100 cells/ml (n¼ 36) had longer PFS
compared with those below the threshold (n¼ 15; median 8.8
versus 2.3months, respectively, HR 0.17, 95% CI 0.06–0.45,
P¼ 0.0004).
Safety
The most frequently reported treatment-emergent AEs of any
grade were IRRs and neutropenia, both occurring in 11 (12%) of
92 patients (supplementary Table S2, available at Annals of
Oncology online). All IRRs except one were non-serious events of
grade 1 or 2. One patient (FL subgroup) experienced an IRR of
grade 4 dyspnea, which was classified as a serious adverse event
(SAE). This resolved, but the patient did not receive further study
medication as per study protocol. Almost all IRRs [9 (82%) of 11
patients] occurred during the first MOR208 infusion; all patients
recovered after the infusion was paused and symptomatic treat-
ment was administered, allowing completion of infusions (except
for the patient with grade 4 dyspnea).
The most common grade3 AEs are summarized in Table 3.
Hematological grade3 AEs were more common in the DLBCL
subgroup. The most frequently reported grade3 AE was neu-
tropenia [6 (17%) of 35 patients with DLBCL and 2 (6%) of 34
patients with FL]. None of the grade3 neutropenia events
were deemed to be SAEs by investigators. In most cases, they
started during cycle 1 or 2 [6 (75%) of 8 patients] and all pa-
tients recovered within 1 week. Temporary interruption of
MOR208 infusion was required in one patient who developed a
grade 4 neutropenia. The majority of patients in the DLBCL
subgroup developing neutropenia had a lymphocyte or neutro-
phil count below the lower limit of the normal reference range
at baseline.
The most frequently reported grade3 non-hematological
AEs were dyspnea and pneumonia. One dyspnea (grade 4) event,
also reported as an IRR, was assessed as related to MOR208. All
three cases of pneumonia were in the DLBCL subgroup and were
reported as not related to MOR208. The majority of patients who
completed3 treatment cycles [37 (76%) of 49 patients, 40%
overall] did not experience any grade3 AEs.
Four (4%) of 92 patients experienced an SAE with a suspected
relationship to MOR208, two in the DLBCL subgroup (febrile
neutropenia; genital herpes) and two in the FL subgroup [dys-
pnea; myelodysplastic syndrome (MDS; relationship to prior
therapies could not be excluded)]. Three (3%) of 92 patients dis-
continued MOR208 due to treatment-related AEs. There were no
treatment-related deaths.
Pharmacokinetics and immunogenicity
The mean terminal elimination half-life of MOR208 was ap-
proximately 16 days. The estimated steady state was reached after
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Table 1. Baseline patient and disease characteristics
Characteristica Non-Hodgkin’s lymphoma subtype cohort
DLBCL FL Other iNHL MCL Total
N535 N5 34 N5 11b N5 12 N5 92
Age, years
Median 71 62 73 64.5 66.5
Range 35–90 40–87 45–83 56–74 35–90
Sex
Male 24 (69) 16 (47) 5 (45) 11 (92) 56 (61)
Female 11 (31) 18 (53) 6 (55) 1 (8) 36 (39)
ECOG PS
0 19 (54) 22 (65) 9 (82) 6 (50) 56 (61)
1 15 (43) 10 (29) 2 (18) 5 (42) 32 (35)
2 1 (3) 2 (6) 0 1 (8) 4 (4)
Ethnicity
White 33 (94) 32 (94) 11 (100) 11 (92) 87 (95)
Other 2 (6) 2 (6) 0 1 (8) 5 (5)
Ann Arbor stage
Stages I–II 4 (11) 5 (15) 0 1 (8) 10 (11)
Stages III–IV 30 (86) 29 (85) 11 (100) 11 (92) 81 (88)
Unknown 1 (3) 0 0 0 1 (1)
International prognostic indexc
High risk 19 (54) 10 (29) – 9 (75) –
Low risk 15 (43) 23 (68) – 3 (25) –
Missing 1 (3) 1 (3) – 0 –
Prior lines of therapy
1 12 (34) 13 (38) 3 (27) 3 (25) 31 (34)
2 8 (23) 4 (12) 2 (18) 1 (8) 15 (16)
3 9 (26) 5 (15) 2 (18) 2 (17) 18 (20)
>3 6 (17) 12 (35) 4 (36) 6 (50) 28 (30)
DoR to most recent treatment
12 months 26 (74) 17 (50) 8 (73) 7 (58) 58 (63)
>12 months 3 (9) 15 (44) 3 (27) 4 (33) 25 (27)
Unknown 6 (17) 2 (6) 0 1 (8) 9 (10)
Time since last therapy
3 months 16 (46) 6 (18) 3 (27) 5 (42) 30 (33)
>3 months 19 (54) 28 (82) 8 (73) 7 (58) 62 (67)
Rituximab refractoryd
Yes 24 (69) 17 (50) 5 (45) 6 (50) 52 (57)
No 11 (31) 17 (50) 6 (55) 6 (50) 40 (43)
Off rituximab >6 months
Yes 21 (60) 29 (85) 10 (91) 11 (92) 71 (77)
No 14 (40) 5 (15) 1 (9) 1 (8) 21 (23)
Prior autologous stem cell transplant 4 (11) 6 (18) 2 (18) 1 (8) 13 (14)
FCGR2A codon 131 statuse
HH 11 (31) 9 (26) 1 (9) 3 (25) 24 (26)
HR 9 (26) 13 (38) 4 (36) 6 (50) 32 (35)
RR 12 (34) 3 (9) 2 (18) 1 (8) 18 (20)
Missing 3 (9) 9 (26) 4 (36) 2 (17) 18 (20)
FCGR3A codon 158 statusf
VV 5 (14) 4 (12) 0 1 (8) 10 (11)
FV 10 (29) 12 (35) 2 (18) 6 (50) 30 (33)
FF 17 (49) 9 (26) 5 (45) 3 (25) 34 (37)
Missing 3 (9) 9 (26) 4 (36) 2 (17) 18 (20)
Data are number of patients (%) unless otherwise stated.
aAs determined at screening or at baseline.
bIncluding nine patients with marginal zone lymphoma and two with chronic lymphocytic leukemia.
cAssessed according to lymphoma subtype-speciﬁc scoring systems: DLBCL, International Prognostic Index; FL, Follicular Lymphoma International
Prognostic Index; MCL, Mantle Cell Lymphoma International Prognostic Index.
dPatients were considered rituximab refractory if they had no response or a response lasting<6months to a prior rituximab-containing therapy.
eDue to a single nucleotide polymorphism, codon 131 of the autosomal FCGR2A gene codes for either histidine (H) or arginine (R).
fDue to a single nucleotide polymorphism, codon 158 of the autosomal FCGR3A gene codes for either valine (V) or phenylalanine (F).
DLBCL, diffuse large B-cell lymphoma; DoR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymph-
oma; iNHL indolent non-Hodgkin’s lymphoma; MCL, mantle cell lymphoma.
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40–50 days, with mean steady-state Cmax and trough levels of
500 and 250 mg/ml, respectively. Anti-drug antibodies were
detected during treatment in only 1/92 patients (1%), indicating
very low immunogenicity forMOR208.
Discussion
This study provides encouraging results for MOR208 monother-
apy in patients with R-R NHL. Objective responses, including
complete responses, were seen in 26% of patients with DLBCL
and 29% with FL. Responses were in many cases durable, as
shown by median durations of 20.1months for DLBCL and not
yet reached for FL and other iNHL, with the longest durations of
response in each of subgroup being>2 years. It was recom-
mended that glucocorticosteroids should be administered as a
part of premedication to prevent IRRs. In view of the weekly fre-
quency of premedication during the initial cycles, a potential
contribution of corticosteroids to treatment efficacy cannot be
ruled out. Thereafter, however, corticosteroids may have been
administered at a maximum of once or twice monthly and thus,
their contribution to the long-term antitumor effect of MOR208
is considered to be negligible. In addition, the observed target le-
sion shrinkage in most patients with a best objective response of
stable disease suggests a therapeutic benefit, especially in patients
with iNHL. Although the design of the current study with a max-
imum treatment period of 3months for patients with stable dis-
ease was appropriate for an initial signal-seeking trial, extending
MOR208 treatment until progression should be investigated in
future clinical studies.
Notably, responses were seen in 10 (22%) of 46 patients with
rituximab refractory disease, indicating the potential of alterna-
tively targeting CD19 to improve outcome in such patients.
Other CD19-targeted agents in clinical development include the
CD19 antibody-drug conjugate, coltuximab ravtansine, the
bispecific T-cell engaging CD19 antibody, blinatumomab and
several anti-CD19 chimeric antigen receptor (CAR) T-cell prod-
ucts. In phase I studies, responses were reported in 7 (28%) of
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Figure 1. Time to and duration of response. aOne patient with stable disease had a late response (PR) after 17 months in follow-up.
Outcome for this patient is not shown in the ﬁgure. CR, complete response; DLBCL, diffuse large B-cell lymphoma; NHL, non-Hodgkin’s
lymphoma; PR, partial response.
Table 2. Investigator assessed best overall response
DLBCL FL Other iNHL MCL Total
N5 35 N534 N5 11 N512 N5 92
Best overall response
Complete response 2 (6) 3 (9) 2 (18) 0 7 (8)
Partial response 7 (20) 7 (21) 1 (9) 0 15 (16)
Stable disease 5 (14) 16 (47) 4 (36) 6 (50) 31 (34)
Progressive disease 11 (31) 4 (12) 3 (27) 5 (42) 23 (25)
Not evaluablea 10 (29) 4 (12) 1(9) 1 (8) 16 (17)
ORR (all patients) 9 (26) 10 (29) 3 (27) 0 22 (24)
ORR (assessable
patients onlyb)
9 (36) 10 (33) 3 (30) 0 22 (29)
DCR (all patients) 14 (40) 26 (76) 7 (64) 6 (50) 53 (58)
Data are number of patients (%).
aRadiological post-baseline response assessment not performed/data
unavailable.
bPost hoc sensitivity analysis excluding patients without post-baseline
radiological tumor assessment.
DLBCL, diffuse large B-cell lymphoma; DCR, disease control rate (com-
pleteþ partial responsesþ stable disease); FL, follicular lymphoma; iNHL,
indolent non-Hodgkin’s lymphoma; MCL, mantle cell lymphoma; ORR,
objective response rate (completeþ partial responses).
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ravtansine [12], and 24 (69%) of 35 patients with R-R NHL
treated with the recommended dose of blinatumomab [13]. In
phase I/II CAR T-cell therapy trials, response rates of 59%–82%
(including complete response rates of 43%–57%) have been re-
ported in patients with R-RNHL [14–17]. Of note, markedly lon-
ger durations of response were noted for patients with complete
compared with partial responses [14, 16]. However, the T-cell-
based therapies are associated with relatively high levels of tox-
icity, including severe neurological events and cytokine release
syndrome [13–17], raising the possibility that such approaches
might be most appropriate for younger, fitter patients treated at
specialist centers. Further studies will be required to determine
the optimum patient populations for the different CD19-targeted
agents.
NK cell-mediated ADCC is predicted to be an important com-
ponent of the mode of action of MOR208. In line with this pre-
diction, PFS was found to be longer in patients with an NK cell
count above a threshold of 100 cells/ml.
MOR208 therapy was generally very well tolerated. The higher
incidence of hematological AEs in the DLBCL subgroup is most
likely attributable to the aggressive nature of this NHL subtype
and shorter time period since the completion of the last treatment
when compared with iNHL subtypes. Several of these heavily pre-
treated patients had baseline neutrophil counts below the lower
limit of the normal reference range, probably as a result of their
most recent antilymphoma therapy. There were few grade3
non-hematological AEs. IRRs were typically mild, and mostly
occurred during the first infusion.
The tolerability of MOR208 provides a rationale for combin-
ation studies, especially in elderly patients or those unsuitable
for high-dose chemotherapy and stem-cell transplantation.
Importantly in this context, MOR208 has shown synergistic
potential in preclinical experimental models with the immuno-
modulatory agent, lenalidomide and the cytotoxic alkylating ni-
trogen mustard, bendamustine [18]. Consequently, MOR208 is
currently being investigated in patients with R-R DLBCL in a
phase II study in combination with lenalidomide (L-MIND;
NCT02399085), and in a phase II/III study, in combination with
bendamustine (B-MIND, NCT02763319). On the basis of pre-
liminary encouraging results for MOR208 plus lenalidomide in
the L-MIND study, [19] MOR208 has now been designated as a
breakthrough therapy for R-R DLBCL by the US Food and Drug
Administration.
In conclusion, single-agent MOR208 showed promising activ-
ity with long-lasting responses in aggressive and iNHL subtypes,
including in patients with rituximab refractory disease. Based on
these data, and the favorable safety and tolerability of MOR208,
further clinical development of combination therapy with
MOR208 is now being undertaken in patients with B-cell
malignancies.
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eNo grade 3 or grade 5 infusion-related reactions were reported.
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; iNHL, in-
dolent non-Hodgkin’s lymphoma; MCL, mantle cell lymphoma; TEAEs,
treatment emergent adverse events.
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